Akebia Therapeutics Downgraded to 'Strong Sell' by Zacks Research

Analysts cite concerns over the company's financial performance and outlook

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company focused on kidney disease treatments, has been downgraded from a 'hold' rating to a 'strong sell' rating by Zacks Research. The analysts cited the company's financial performance and future outlook as reasons for the downgrade.

Why it matters

Akebia Therapeutics is a key player in the kidney disease treatment market, and this downgrade from a respected research firm could signal broader concerns about the company's prospects. The news may impact investor sentiment and the stock price, potentially affecting the company's ability to raise capital and fund its research and development efforts.

The details

In a research note, Zacks Research analysts lowered their rating on Akebia Therapeutics from 'hold' to 'strong sell', citing the company's financial performance and future outlook. The analysts also reduced their target price on the stock from $6.00 to $4.00, indicating a potential further decline in the share price.

  • Zacks Research issued the downgrade on Thursday, February 28, 2026.

The players

Akebia Therapeutics

A biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease.

Zacks Research

An equity research firm that provides investment research and analysis to institutional and individual investors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade of Akebia Therapeutics by Zacks Research highlights the ongoing challenges facing the company in the kidney disease treatment market. Investors will be closely watching the company's financial performance and strategic initiatives in the coming months to assess its long-term viability.